Table 2. Relationship between PD-L1 protein expression and the clinicopathological feature.
| Clinicopathological feature | Detection method of PD-L1 | Studies | Heterogeneity |
OR (95% CI) | P value | |
|---|---|---|---|---|---|---|
| P value | I2 | |||||
| Gender | IHC | 6 | 0.08 | 49% | 1.18 (0.87-1.61) | 0.29 |
| QIF | 1 | 0.18 | 44% | 0.97 (0.58-1.63) | 0.92 | |
| Total | 7 | 0.10 | 42% | 1.12 (0.86-1.46) | 0.39 | |
| Smoking Status | IHC | 4 | 0.12 | 49% | 0.72 (0.49-1.06) | 0.10 |
| QIF | 1 | NA | NA | 0.72 (0.28-1.81) | 0.48 | |
| Total | 5 | 0.21 | 32% | 0.72 (0.51-1.03) | 0.07 | |
| Differentiation | IHC | 7 | 0.88 | 0% | 0.53 (0.39-0.72) | <0.0001 |
| QIF | 0 | NA | NA | NA | NA | |
| Total | 7 | 0.88 | 0% | 0.53 (0.39- 0.72) | <0.0001 | |
| Histology | IHC | 5 | 0.08 | 53% | 1.08 (0.60-1.95) | 0.80 |
| QIF | 1 | 0.03 | 80% | 0.54 (0.18-1.64) | 0.27 | |
| Total | 6 | 0.01 | 63% | 0.86 (0.52-1.45) | 0.58 | |
| Tumor depth | IHC | 3 | 0.16 | 46% | 0.64 (0.37-1.10) | 0.11 |
| QIF | NA | NA | NA | NA | NA | |
| Total | 3 | 0.16 | 46% | 0.64 (0.37-1.10) | 0.11 | |
| Status of lymph node | IHC | 5 | 0.001 | 78% | 0.79 (0.36-1.77) | 0.57 |
| QIF | NA | NA | NA | NA | NA | |
| Total | 5 | 0.001 | 78% | 0.79 (0.36-1.77) | 0.57 | |
| Stage | IHC | 5 | 0.001 | 77% | 0.67 (0.30-1.50) | 0.33 |
| QIF | 1 | 0.60 | 0% | 1.23 (0.80-1.90) | 0.34 | |
| Total | 6 | 0.003 | 70% | 0.86 (0.51-1.45) | 0.56 | |
Abbreviations: PD-L1, programmed cell death ligand1; IHC, immunohistochemistry; QIF, quantitative immunofluorescence; NA, not applicable; OR, odds ratio; CI, confidence interval.